CMMB - Chemomab stock jumps 16% after FDA cleared CM-101 application for bile ducts disease

Chemomab Therapeutics (NASDAQ:CMMB) soars 15.5% premarket after announcing that the FDA has cleared its Investigational New Drug (IND) application for CM-101, a CCL24-neutralizing antibody for the treatment of the rare disease primary sclerosing cholangitis (PSC). The Phase 2 SPRING trial assessing CM-101 as a potential treatment for PSC is already underway in Europe and Israel and is now being expanded to include U.S. sites. The initial clinical readout is expected in 2022. CM-101 appeared safe and well-tolerated in Phase 1a and 1b clinical studies in healthy volunteers and non-alcoholic fatty liver disease patients. The drug is currently being assessed in Phase 2 SPRING trial in PSC and in a Phase 2 liver fibrosis study. A third Phase 2 trial in systemic sclerosis is expected to begin in early 2022. PSC is a rare and serious disease of the bile ducts in the liver. In September, Chemomab collaborated with Leeds University in systemic

For further details see:

Chemomab stock jumps 16% after FDA cleared CM-101 application for bile ducts disease